Type of security: Stock
Sector: Health Care
Industry: Major Pharmaceuticals
Market Capitalization: 533.24 M
The data is delayed by 15 minutes.
Description: Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. The company has three clinical development programs and one drug discovery program underway. Its clinical development programs include CO-1686, an oral epidermal growth factor receptor and mutant-selective covalent inhibitor, which is in Phase I/II clinical trials for the treatment of non-small cell lung cancer; rucaparib, an oral inhibitor of poly polymerase that is being explored in Phase II or III clinical trials for treating ovarian cancer patients, and Phase II clinical trials for treating pancreatic cancer patients; and lucitanib, an oral inhibitor of the tyrosine kinase Phase I/IIa clinical trials for the treatment of breast and lung cancers. The company's drug discovery program includes the discovery of cKIT inhibitor targeting resistance mutations for the treatment of GIST, a gastrointestinal cancer. It has license agreements w
|Shares Outstanding||38.39 M||EPS||EPS Growth - 4 Quarters||EPS Growth - Q/Q|
|EPS Growth - Y/Y||Sales Growth - 4 Quarters||Sales Growth - Q/Q||P/E|
|P/E To EPS Growth||P/S||P/BV||2.11||Price/Cash Per Share|
|Price/Free Cash Flow||-4.47||ROA||-27.31%||ROE||-76.19%||ROI|
|Current Ratio||7.93||Quick Ratio||Long Term Debt/Equity||Debt Ratio||0.22|
|Gross Margin||Operating Margin||Net Profit Margin||Dividend Payout Ratio|
|Cash From Financing Activities||1.19 M||Cash From Investing Activities||-143.03 M||Cash From Operating Activities||-48.41 M||Gross Profit|
|Net Profit||-63.14 M||Operating Profit||-64.22 M||Total Assets||704.71 M||Total Current Assets||441.7 M|
|Total Current Liabilities||55.68 M||Total Debt||287.5 M||Total Liabilities||452.12 M||Total Revenue|
|High 52 week||32.67||Low 52 week||3.12||Last close||3.21||Last change||2.88%|
|RSI||20.96||Average true range||0.29||Beta||1.33||Volume||1.42 M|
|Simple moving average 20 days||-17.78%||Simple moving average 50 days||-36.87%||Simple moving average 200 days||-80.19%|
|Performance Week||1.58%||Performance Month||-43.19%||Performance Quart||-73.97%||Performance Half||-84.87%|
|Performance Year||-87.99%||Performance Year-to-date||-82.13%||Volatility daily||3.69%||Volatility weekly||8.26%|
|Volatility monthly||16.93%||Volatility yearly||58.65%||Relative Volume||1318.58%||Average Volume||3.84 M|
|New High||New Low|
2020-05-28 08:00:00 | Clovis Oncology Announces New Recommendations for Rubraca® rucaparib Tablets in Updated National Comprehensive Cancer Network NCCN Guidelines® for the Treatment of Metastatic Castration-Resistant Prostate Cancer mCRPC
2020-05-21 16:10:00 | Clovis Oncology Announces Presentations at 2020 ASCO Virtual Scientific Program
2020-05-21 14:24:29 | Clovis Oncology Needs a Savior
2020-05-19 18:53:20 | 8 Biotechs Tapping Secondary Markets for $3 Billion
2020-05-19 15:09:19 | Why Clovis Oncology's Stock Is Trading Lower Today
2020-05-18 20:05:00 | Clovis Oncology Announces Pricing of Public Offering of Common Stock
2020-05-18 16:02:00 | Clovis Oncology Announces Proposed Offering of Common Stock
2020-05-18 11:45:03 | Clovis' CLVS Rubraca Gets FDA Approval for Prostate Cancer
2020-05-16 11:31:00 | Clovis Oncology Secures FDA Approval for Rubraca in Prostate Cancer
2020-05-15 14:30:00 | Rubraca® Rucaparib Approved in the U.S. as Monotherapy Treatment for Patients with BRCA1/2-Mutant, Metastatic Castration-Resistant Prostate Cancer mCRPC Who Have Been Treated with Androgen Receptor-Directed Therapy and a Taxane-Based Chemotherapy
2020-05-14 10:18:02 | Is Clovis Oncology CLVS Stock a Solid Choice Right Now?
2020-05-11 11:00:00 | Why Clovis Oncology Stock Marched Higher in April
2020-05-06 11:17:03 | Clovis CLVS Q1 Earnings and Revenues Surpass Estimates
2020-05-06 11:10:00 | Edited Transcript of CLVS earnings conference call or presentation 5-May-20 8:30pm GMT
2020-05-06 11:02:43 | Clovis Oncology CLVS Q1 2020 Earnings Call Transcript
2020-05-06 08:02:42 | Benzinga Pro's Top 5 Stocks To Watch for Wed., May 6, 2020: SNY, GRUB, CLVS, NTDOY, FDS
2020-05-05 19:05:11 | Clovis Oncology CLVS Reports Q1 Loss, Tops Revenue Estimates
2020-05-05 16:05:00 | Clovis Oncology Announces First Quarter 2020 Operating Results
2020-05-03 09:25:12 | Attention Biotech Investors: Mark Your Calendar For These May PDUFA Dates
2020-04-29 16:05:00 | Clovis Oncology to Present at the Bank of America Health Care Conference 2020
2020-04-28 12:34:04 | Will Clovis Oncology CLVS Report Negative Earnings Next Week? What You Should Know
2020-04-22 09:00:01 | Are Options Traders Betting on a Big Move in Clovis Oncology CLVS Stock?
2020-04-15 12:00:04 | Clovis CLVS Upgraded to Buy: Here's Why
2020-04-14 17:08:00 | Clovis Oncology Announces Debt Exchange Transaction
2020-04-09 10:04:45 | Clovis Oncology Analyst Turns Bearish Ahead Of PDUFA Date For Rubraca
2020-04-03 17:50:09 | Clovis Oncology CLVS Gains As Market Dips: What You Should Know
2020-03-25 11:30:03 | Why Is Clovis CLVS Down 41.6% Since Last Earnings Report?
2020-03-20 09:36:01 | Is the Options Market Predicting a Spike in Clovis Oncology CLVS Stock?
2020-03-19 17:50:09 | Clovis Oncology CLVS Gains But Lags Market: What You Should Know
2020-03-11 17:50:09 | Clovis Oncology CLVS Stock Moves -1.59%: What You Should Know
2020-03-03 08:30:00 | Clovis Oncology to Present at the Barclays Global Healthcare Conference
2020-02-25 10:12:03 | Clovis CLVS Q4 Loss Wider Than Expected, Revenues Beat
2020-02-25 02:06:26 | Edited Transcript of CLVS earnings conference call or presentation 24-Feb-20 9:30pm GMT
2020-02-24 18:15:11 | Clovis Oncology CLVS Reports Q4 Loss, Tops Revenue Estimates
2020-02-24 16:05:00 | Clovis Oncology Announces 2019 Operating Results
2020-02-21 11:30:04 | Is Clovis Oncology CLVS Outperforming Other Medical Stocks This Year?
2020-02-19 10:13:03 | What's in Store for Aimmune AIMT This Earnings Season?
2020-02-19 09:39:02 | Is a Beat in the Cards for Clovis' CLVS Earnings in Q4?
2020-02-19 08:39:01 | Implied Volatility Surging for Clovis Oncology CLVS Stock Options
2020-02-17 12:30:05 | Clovis Oncology CLVS Expected to Beat Earnings Estimates: Can the Stock Move Higher?
2020-02-17 08:46:01 | 5 Drug/Biotech Stocks Likely to Beat Q4 Earnings Estimates
2020-02-11 16:05:00 | Clovis Oncology to Present at the 9th Annual SVB Leerink Healthcare Conference
2020-02-06 15:34:06 | 4 Stocks Looking Higher During Earnings Season
2020-02-06 11:17:00 | Four stocks to watch this week include Clovis Oncology and 3D Systems
2020-02-03 09:44:02 | Is a Beat in the Cards for Humana's HUM Earnings in Q4?